Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Goodwill (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Goodwill for 5 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Goodwill rose 3.93% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 3.93% year-over-year, with the annual reading at $8.6 million for FY2025, N/A changed from the prior year.
  • Goodwill for Q4 2025 was $8.7 million at Neuphoria Therapeutics, up from $8.7 million in the prior quarter.
  • The five-year high for Goodwill was $9.2 million in Q2 2022, with the low at $8.4 million in Q4 2024.
  • Average Goodwill over 4 years is $8.7 million, with a median of $8.7 million recorded in 2025.
  • The sharpest move saw Goodwill decreased 5.12% in 2023, then grew 3.93% in 2025.
  • Over 4 years, Goodwill stood at $9.2 million in 2022, then decreased by 5.12% to $8.7 million in 2023, then fell by 3.86% to $8.4 million in 2024, then grew by 3.93% to $8.7 million in 2025.
  • According to Business Quant data, Goodwill over the past three periods came in at $8.7 million, $8.7 million, and $8.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.